Abbott Laboratories (NYSE:ABT) reported on Wednesday a notable increase in its first quarter sales for 2024, which rose by 2.2% to reach $9.9 billion, surpassing analysts’ expectations. However, the company experienced a decline in net earnings, which fell by 7.0% to $1.2 billion, and diluted earnings per share (EPS) decreased by 6.7% to $0.70.

Despite the downturn in profitability, the healthcare giant has adjusted its financial outlook upwards for the year. Abbott now forecasts a full-year diluted EPS on a GAAP basis to be between $3.25 and $3.40. Additionally, the company’s full-year 2024 organic sales growth guidance is projected to range from 8.5% to 10.0%.

Chairman and CEO Robert B. Ford expressed optimism about the company’s performance, stating, “Our first-quarter results reflect a strong start to the year, and we are raising our full-year sales and EPS guidance […] This was the fifth consecutive quarter that we delivered double-digit organic sales growth in our underlying base business.” This statement highlights the company’s confidence in its operational strength and its ability to sustain growth amidst challenging market conditions.

Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Abbott Laboratories.
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Abbott Laboratories.